On the face of it the rules governing trademarks seem straight forward; basically you have to have a distinct “mark” so the public will be able to identify the source of the goods or services being offered. The two no-no’s are trying to use a merely descriptive word (”Delicious” cookies) or a generic term (”Soap” as your brand). For Bayer, the aspirin people, trying to register a new trademark (ASPRINA) turned into a true headache.
The irony in this mini-drama, of course, is that Bayer’s chemists were the first to come up with aspirin as we know it. According to the Bayer web site:
1897 - Chemist, Felix Hoffmann, at Bayer in Germany, chemically synthesizes a stable form of ASA powder that relieves his father’s rheumatism. The compound later becomes the active ingredient in aspirin named - “a” from acetyl, “spir” from the spirea plant (which yields salicin) and “in,” a common suffix for medications.
Yet, 110 years later, when Bayer submitted ASPRINA to the PTO as a mark to be used in conjunction with analgesic goods (presumably aspirin), they were rejected on the grounds that the mark was merely descriptive. Bayer appealed to the TTAB, which concluded that consumers could be confused into thinking ASPRINA was just a variation on the generic aspirin.
Bayer then escalated its appeal to the Federal Circuit; again Bayer was rebuffed. The Court found that visually, and in the commercial context in which it would be used, consumers might be confused into thinking this label was a generic description of what was in the package.
So Bayer, which has made a significant effort to make us think “Bayer” when we think of aspirin (see image of package - “aspirin” is about 1/5 the size of “Bayer”), has found that in the United States it can’t go back and start selling us Aspirina aspirin. It would be like trying sell Macintosh McIntoshes.


Entries (RSS)